• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Saturday, February 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

The Rivkin Center awards $1.185 million in ovarian cancer research grants

Bioengineer by Bioengineer
April 11, 2018
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Seattle, WA (April 11, 2018) — The Rivkin Center for Ovarian Cancer, a Seattle-based 501(c)(3), announced that it has awarded $1.185 million in ovarian cancer research grants for 2018. The amount funded was a 10% increase from the previous year.

The grant recipients include researchers from the United States, Italy, Australia, and Israel whose research projects focus on topics such as prevention and early detection, DNA repair, chemotherapy resistance and novel therapies including immunotherapy. Sixty-four percent of the awardees are women.

"The projects selected this year have tremendous potential to move the progress of ovarian cancer research forward, and help women live longer, healthier lives," said Joe White, Executive Director of the Rivkin Center for Ovarian Cancer.

Ovarian cancer is the most deadly gynecological cancer, killing more than 22,000 women in the United States each year. Despite this, ovarian cancer continues to be underfunded by federal funding agencies as compared to other cancers. The Rivkin Center plays a pivotal role in helping the forward progress of ovarian cancer research to improve early detection and discover new life-saving treatments. The Rivkin Center is the largest private funder of international ovarian cancer research and has awarded more than $11 million in grants to-date. Notably, a Rivkin-funded study was the first to identify the signs and symptoms of ovarian cancer when none were thought to exist.

2017 Rivkin Center Pilot Study Grant Awardee Dr. Nadine Hempel of the Penn State College of Medicine explains the impact: "If you're an ovarian cancer researcher, you've leaned on the Rivkin Center to advance your research."

###

ABOUT THE RIVKIN CENTER FOR OVIARIAN CANCER

Since its inception in 1996, the Rivkin Center has been a principal catalyst for national and international research efforts aimed at finding solutions to ovarian cancer. The center looks beyond institutional boundaries and works collaboratively with scientists and physicians worldwide at the forefront of ovarian cancer research.

As the largest private funder of international ovarian cancer research projects, the Rivkin Center for Ovarian Cancer funds cutting-edge ovarian cancer research, high-risk screening, and educational programs for women in an effort to keep them healthy.

Media Contacts:

Katie Olsen, GreenRubino
[email protected]
(206) 447-4747

Heike Malakoff
Director of Marketing and Education, the Rivkin Center for Ovarian Cancer
[email protected]
(206) 963-6556

Media Contact

Katie Olsen
[email protected]
206-447-4747
@greenrubino

Home

Share14Tweet7Share2ShareShareShare1

Related Posts

Decoding Prostate Cancer Origins via snFLARE-seq, mxFRIZNGRND

February 7, 2026

Digital Health Perspectives from Baltic Sea Experts

February 7, 2026

Exploring Decision-Making in Dementia Caregivers’ Mobility

February 7, 2026

Succinate Receptor 1 Limits Blood Cell Formation, Leukemia

February 7, 2026
Please login to join discussion

POPULAR NEWS

  • Robotic Ureteral Reconstruction: A Novel Approach

    Robotic Ureteral Reconstruction: A Novel Approach

    82 shares
    Share 33 Tweet 21
  • Digital Privacy: Health Data Control in Incarceration

    63 shares
    Share 25 Tweet 16
  • Study Reveals Lipid Accumulation in ME/CFS Cells

    57 shares
    Share 23 Tweet 14
  • Breakthrough in RNA Research Accelerates Medical Innovations Timeline

    53 shares
    Share 21 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Decoding Prostate Cancer Origins via snFLARE-seq, mxFRIZNGRND

Digital Health Perspectives from Baltic Sea Experts

Florida Cane Toad: Complex Spread and Selective Evolution

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 73 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.